Acceleron discontinues ACE-2494 due to antidrug antibodies

Acceleron discontinued development of ACE-2494 due to the frequency of antidrug antibodies observed among healthy volunteers in a Phase I trial.

Acceleron Pharma Inc. (NASDAQ:XLRN) was developing ACE-2494 as a potential treatment of neuromuscular disorders. ACE-2494 is a ligand trap that inhibits MSTN, GDF11, activin A and activin B...